The Archer® FusionPlex Sarcoma panel is a targeted next-generation sequencing (NGS) product to simultaneously detect and identify fusions of 26 genes associated with soft tissue cancers. FusionPlex uses RNA instead of DNA as input material, which allows for more accurate and more cost-effective fusion detection than DNA-based hybrid capture techniques. FusionPlex places gene-specific primers near known fusion breakpoints to identify RNA abnormalities with a single primer. Because FusionPlex can identify known and novel alterations, with a limited number of primers, it can detect fusions more efficiently and accurately than DNA-based approaches.
Comprehensive Fusion Detection
AMP chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.
Quiver® Fusion Database
Powerful fusion analysis combined with a curated database of relevant known translocations.
Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.
Simple, Lyophilized Workflow
Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turnaround time.
Input cfDNA Required
Unique Molecular On-Target %
Illumina® and Ion Torrent™
Fresh frozen and FFPE
*Input recommendations for FFPE samples vary depending on Archer PreSeq® RNA QC score; 50ng input recommended in absence of PreSeq screening